OTC · NMDBF
NeonMind Biosciences Inc.
$0.01$0.00 (0.0%)
NeonMind Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.67% below the high.
Loading market information…
OTC · GLSHQ · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Gelesis Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Gelesis Holdings, Inc.’s next earnings report is currently expected on Nov 16, 2026, with estimated earnings per share of -$0.34. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Gelesis Holdings, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Gelesis Holdings, Inc. operated as a commercial-stage biotherapeutics company, concentrating on the development of biomimetic solutions. Its core mission revolved around addressing the root causes of obesity and various chronic gastrointestinal ailments. Among its offerings was PLENITY, an orally administered, non-stimulant, and non-systemic product designed to assist with weight management. The company's pipeline also included several other promising developments: GS200, targeting weight reduction for individuals with prediabetes and type 2 diabetes; and GS500, intended for the treatment of functional constipation. Furthermore, Gelesis had a pre-clinical stage product, GS300, in development for conditions such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Founded in Boston, Massachusetts, in 2006, the company established its headquarters there. Regrettably, on October 30, 2023, Gelesis Holdings, Inc., alongside its affiliates, formally initiated voluntary Chapter 7 liquidation proceedings in the U.S. Bankruptcy Court for the District of Delaware.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:09 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2021 | Sep 30, 2021 | -$5.40 | $3.01M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.01$0.00 (0.0%)
NeonMind Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.67% below the high.
$0.00-$0.00 (0.0%)
MobileSmith, Inc.: Healthcare · Medical - Healthcare Information Services.
$0.00$0.00 (0.0%)
EastWest Bioscience Inc.: Healthcare · Medical - Pharmaceuticals.
$0.00-$0.04 (-99.5%)
E-Qure Corp.: Healthcare · Medical - Devices.
$0.00+$0.00 (+9,900.0%)
Gene Biotherapeutics, Inc.: Healthcare · Biotechnology.
$0.00$0.00 (0.0%)
Capha Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00-$0.04 (-99.75%)
American CryoStem Corporation: Healthcare · Biotechnology.
$0.00+$0.00 (0.0%)
GeneThera, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.33% below the high.
